Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Med Food ; 25(2): 177-182, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34726501

RESUMEN

To evaluate the effect of Banaba (Lagerstroemia speciosa) on metabolic syndrome (MetS), insulin sensitivity, and insulin secretion. A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients with diagnosis of MetS according to the International Diabetes Federation criteria. Body weight, waist circumference, and blood pressure were evaluated. Fasting plasma glucose (FPG) and insulin concentrations were measured every 30 min during 2 h after a 75-g dextrose load. Lipid profile was determined before and after the pharmacological intervention. Twelve patients received Banaba (500 mg) twice a day, before breakfast and dinner for 12 weeks. The remaining 12 patients received placebo at the same dosage. Body mass index, area under the curve (AUC) of glucose and insulin, insulin sensitivity, total insulin secretion, and the first phase of insulin secretion were calculated. After Banaba administration, there were significant decreases in systolic blood pressure (SBP) (121.5 ± 12.9 vs. 116.3 ± 9.8 mmHg, P = .050), FPG (5.9 ± 0.4 vs. 5.7 ± 0.4 mmol/L, P = .034), triglycerides (TG) (2.3 ± 0.4 vs. 1.7 ± 0.5 mmol/L, P = .021), very low-density lipoprotein (VLDL) (0.5 ± 0.1 vs. 0.3 ± 0.1 mmol/L, P = .021), AUC of insulin (50,675 ± 14,309 vs. 37,983 ± 19,298 mmol/L, P = .017), and insulinogenic index (0.4 ± 0.2 vs. 0.3 ± 0.2, P = .047). Eight patients (67%) of the Banaba group showed remission of MetS. In the placebo group, there was a downward trend toward statistical significance in the Stumvoll index (910.3 ± 514.1 vs. 651.0 ± 405.2, P = .062). Banaba administration leads to remission of MetS and a significant decrease in SBP, FPG, TG, VLDL, AUC of insulin, and total insulin secretion. Clinical Trial Registration number: NCT02767869.


Asunto(s)
Resistencia a la Insulina , Lagerstroemia , Síndrome Metabólico , Glucemia , Método Doble Ciego , Humanos , Insulina/metabolismo , Secreción de Insulina , Lagerstroemia/metabolismo , Síndrome Metabólico/tratamiento farmacológico
2.
Drug Chem Toxicol ; 45(5): 2361-2370, 2022 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-34225555

RESUMEN

Drug-induced liver injury is a common cause of acute liver failure. Dapsone is increasingly used in combination with rifampicin for the treatment of leprosy and also for several dermatological disorders. Clinically, abnormal liver function and focal bile duct destruction were reported after dapsone therapy. Lagerstroemia speciosa Pers., commonly known as Banaba has been traditionally used to treat various ailments including diabetes and obesity due to its antioxidant and anti-inflammatory efficacies. This study investigated the hepatoprotective effect of ethanolic banaba leaves extract (EBLE) against dapsone-induced hepatotoxicity in rats. Dapsone (30 mg/kg, i.p.) was administered twice daily for 30 days. In separate groups, rats were post-treated orally with EBLE (250 and 500 mg/kg) and silymarin (100 mg/kg) once daily for 30 days after dapsone administration. The marker enzymes of hepatotoxicity, oxidative stress markers, inflammatory markers and histopathology of liver were done. HPTLC analysis confirmed the presence of 12.87 µg of corosolic acid per mg of EBLE. Dapsone administration-induced significant (p < 0.001) elevation of marker enzymes of hepatotoxicity in serum. This treatment also increased lipid peroxidation (p < 0.001) and pro-inflammatory markers (tumor necrosis factor-alpha, transforming growth factor-beta, and nuclear factor kappa-B) expressions (p < 0.001) and decreased antioxidants (p < 0.001) such superoxide dismutase, catalase and glutathione in the liver tissue. All these abnormalities were significantly (p < 0.001) mitigated after EBLE (500 mg/kg) and silymarin post-treatments. The results of this study suggest that silymarin and EBLE can be used for dapsone-induced hepatotoxicity.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas , Lagerstroemia , Silimarina , Animales , Antioxidantes/farmacología , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Dapsona/toxicidad , Etanol/toxicidad , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Peroxidación de Lípido , Hígado , Estrés Oxidativo , Extractos Vegetales/farmacología , Ratas , Silimarina/farmacología
3.
Artículo en Inglés | MEDLINE | ID: mdl-33167849

RESUMEN

BACKGROUND: Dysbiosis is related to changes in the composition and behaviour of intestinal microbiota, which may contribute to an age-related decline in metabolic and immune system functioning (immune-senescence). OBJECTIVE: The microbiota-targeted dietary and probiotic interventions have been shown to favorably affect the host health by an enhancement of antioxidant activity, improving immune homeostasis, suppression of chronic inflammation, regulation of metabolism and prevention of insulin resistance. RESULTS: In our study, the use of specific probiotics strains improved the serum concentration of glycemic markers, thereby promoting better overall health. CONCLUSION: Probiotics may help correct defects in the gut microbial environment improving metabolic parameters, such as blood sugar levels, glycosylated hemoglobin and a decrease in body weight.


Asunto(s)
Glucemia/efectos de los fármacos , Colecalciferol/uso terapéutico , Microbioma Gastrointestinal , Control Glucémico , Intestinos/microbiología , Lagerstroemia , Extractos Vegetales/uso terapéutico , Probióticos/uso terapéutico , Adulto , Albania , Biomarcadores/sangre , Glucemia/metabolismo , Colecalciferol/efectos adversos , Método Doble Ciego , Disbiosis , Femenino , Hemoglobina Glucada/metabolismo , Humanos , Italia , Lagerstroemia/química , Masculino , Persona de Mediana Edad , Extractos Vegetales/efectos adversos , Hojas de la Planta , Probióticos/efectos adversos , Factores de Tiempo , Resultado del Tratamiento , Pérdida de Peso/efectos de los fármacos
4.
Environ Toxicol ; 35(11): 1225-1233, 2020 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-32697429

RESUMEN

Hepatocellular carcinoma is the second leading cause of cancer-related mortality worldwide. Lagerstroemia speciosa Pers. (Lythraceae) commonly known as Banaba has been used in different forms in traditional medicinal systems for treating various diseases which include diabetes and obesity. In this study, we investigated the cytotoxic potential of ethanolic Banaba leaf extract (EBLE) in HepG2 cells. The phytochemical analysis of EBLE was performed by HPTLC. HepG2 cells were treated with EBLE at 25, 50, 100, and 150 µg/mL concentrations, and cytotoxicity was evaluated by MTT assay. Oxidative stress was assessed by the evaluation of lipid peroxidation, superoxide dismutase, and reduced glutathione. Apoptosis-related morphology was investigated by acridine orange and ethidium bromide (AO/EB) dual staining. Mitochondrial membrane potential (ΔΨm) was evaluated by JC-1 staining. Apoptosis-related marker genes were evaluated by qPCR. HPTLC analysis confirmed the presence of corosolic acid (12.87 µg/mg), berberine (3.19 µg/mg), and gallic acid (2.94 µg/mg) in EBLE. EBLE treatments caused significant and concentration-dependent cytotoxicity and oxidative stress in HepG2 cells. Dual staining with AO/EB confirmed membrane distortion and nuclear chromatin condensation upon EBLE treatments. JC-I staining revealed the loss of ΔΨm. Furthermore, at a molecular level, EBLE treatments interfere with Bax/Bcl-2 homeostasis and induced the pro-apoptotic marker genes such as cytochrome c, Apaf-1, and caspases 9 and 3. EBLE treatments caused cytotoxicity in HepG2 cells, and this could be due to the induction of oxidative stress and apoptosis via the intrinsic or mitochondrial pathway.


Asunto(s)
Antineoplásicos/toxicidad , Extractos Vegetales/toxicidad , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Carcinoma Hepatocelular/patología , Caspasa 9 , Células Hep G2 , Humanos , Lagerstroemia , Neoplasias Hepáticas/patología , Mitocondrias/metabolismo , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/farmacología , Proteínas Proto-Oncogénicas c-bcl-2 , Triterpenos
5.
Trials ; 20(1): 24, 2019 Jan 07.
Artículo en Inglés | MEDLINE | ID: mdl-30616613

RESUMEN

BACKGROUND: Prediabetes describes a state of hyperglycemia outside of normal limits that does not meet the criteria for diabetes diagnosis, is generally symptomless, and affects an estimated 38% of adults in the United States. Prediabetes typically precedes the diagnosis of type 2 diabetes, which accounts for increased morbidity and mortality. Although the use of dietary and herbal supplements is popular worldwide, and a variety of single herbal medicines have been examined for glycemic management, the potential of increasingly common polyherbal formulations to return glycemic parameters to normal ranges among adults with prediabetes remains largely unexplored. The purpose of this study is to evaluate the efficacy of a commercially available, polyherbal dietary supplement on glycemic and lipid parameters in prediabetic individuals. METHODS: In this multi-site, double-blinded, randomized controlled clinical trial, 40 participants with prediabetes will be randomized to either a daily oral polyherbal dietary supplement (GlucoSupreme™ Herbal; Designs for Health®, Suffield, CT, USA; containing cinnamon bark (Cinnamomum cassia), banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid), kudzu root (Pueraria lobata standardized to 40% isoflavones), fenugreek seed (Trigonella foenum-graceum standardized to 60% saponins), gymnema leaf (Gymnema sylvestre standardized to 25% gymnemic acid), American ginseng root (Panax quinquefolius standardized to 5% ginsenosides), and berberine HCl derived from bark (Berberis aristata)) or placebo for 12 weeks. Short-, medium-, and comparatively long-term markers of glycemic control (blood glucose and fasting insulin, fructosamine, and glycated hemoglobin/A1c, respectively), and other glycemic parameters (GlycoMark, ß-cell function, and insulin sensitivity/resistance) will be obtained. Lipid profile (total cholesterol, LDL, HDL, and triglycerides), inflammation (hs-CRP), progression to type 2 diabetes mellitus, as well as safety indices (ALT, AST) will be obtained. An intention-to-treat analysis will be used to assess changes in study outcomes. DISCUSSION: Treatment options for adults with prediabetes are currently limited. This study aims to evaluate the safety and efficacy of a commercially available dietary supplement in the popular, but as yet insufficiently studied, category of polyherbal formulas for the management of glycemic parameters and other biomarkers associated with prediabetes. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03388762 . Retrospectively registered on 4 January 2018.


Asunto(s)
Suplementos Dietéticos , Extractos Vegetales/administración & dosificación , Estado Prediabético/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto , Adulto , Interpretación Estadística de Datos , Método Doble Ciego , Humanos , Estudios Multicéntricos como Asunto , Evaluación de Resultado en la Atención de Salud , Fitoterapia , Tamaño de la Muestra
6.
New Phytol ; 222(1): 408-424, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30472753

RESUMEN

Pentacyclic triterpenes (PCTs) represent a major class of bioactive metabolites in banaba (Lagerstroemia speciosa) leaves; however, biosynthetic enzymes and their involvement in the temporal accumulation of PCTs remain to be studied. We use an integrated approach involving transcriptomics, metabolomics and gene function analysis to identify oxidosqualene cyclases (OSCs) and cytochrome P450 monooxygenases (P450s) that catalyzed sequential cyclization and oxidative reactions towards PCT scaffold diversification. Four monofunctional OSCs (LsOSC1,3-5) converted the triterpene precursor 2,3-oxidosqualene to either lupeol, ß-amyrin or cycloartenol, and a multifunctional LsOSC2 formed α-amyrin as a major product along with ß-amyrin. Two CYP716 family P450s (CYP716A265, CYP716A266) catalyzed C-28 oxidation of α-amyrin, ß-amyrin and lupeol to form ursolic acid, oleanolic acid and betulinic acid, respectively. However, CYP716C55 catalyzed C-2α hydroxylation of ursolic acid and oleanolic acid to produce corosolic acid and maslinic acid, respectively. Besides, combined transcript and metabolite analysis suggested major roles for the LsOSC2, CYP716A265 and CYP716C55 in determining leaf ursane and oleanane profiles. Combinatorial expression of OSCs and CYP716s in Saccharomyces cerevisiae and Nicotiana benthamiana led to PCT pathway reconstruction, signifying the utility of banaba enzymes for bioactive PCT production in alternate plant/microbial hosts that are more easily tractable than the tree species.


Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Transferasas Intramoleculares/metabolismo , Lagerstroemia/metabolismo , Plantas Medicinales/metabolismo , Árboles/metabolismo , Triterpenos/química , Biocatálisis , Vías Biosintéticas , Regulación de la Expresión Génica de las Plantas , Hidroxilación , Metaboloma , Oxidación-Reducción , Hojas de la Planta/metabolismo , Plantas Modificadas Genéticamente , ARN Mensajero/genética , ARN Mensajero/metabolismo , Estaciones del Año , Factores de Tiempo , Nicotiana/genética , Transcriptoma/genética , Triterpenos/metabolismo
7.
High Blood Press Cardiovasc Prev ; 24(1): 13-18, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27339779

RESUMEN

BACKGROUND: There is an increasing interest for combined nutraceuticals that can act on several points of lipid and glucose metabolism with preventive purposes. However, the simple assemblage of nutraceuticals with potentially additive mechanism of action need to be clinically tested. METHODS: To assess the effects of a combination of nutraceuticals based on artichoke, red yeast rice, banaba, and coenzyme Q10, we performed a double bind, cross-over designed trial versus placebo in 30 adults with LDL cholesterol suboptimal in primary prevention of cardiovascular disease. After a period of 3 weeks of dietary habits correction, patients began a period of 6 weeks of treatment with nutraceutical or placebo, followed by 2 weeks of washout and finally 6 weeks in cross-over. Data related to lipid pattern, insulin resistance, renal function, liver and CPK have been obtained at each visit. RESULTS: In particular, the after the nutraceutical treatment the enrolled patients experienced a significant improvement in total cholesterol (-13.6 %), LDL-C (-18.2 %), non-HDL-C (-15 %), glutamic oxaloacetic transaminase (-10 %), glutamate-pyruvate transaminase (-30.9 %), and hs-CRP (-18.2 %) versus placebo. No changes have been observed in the other investigated parameters in both groups. CONCLUSIONS: The tested combination of nutraceuticals has shown clinical efficacy in the reduction of total cholesterol, non-HDL, LDL and triglycerides, while improving the level of liver transaminases and high sensitivity C-reactive protein. Further confirmation are needed to verify these observations on the middle and long term with a larger number of subjects.


Asunto(s)
Antiinflamatorios/administración & dosificación , Glucemia/efectos de los fármacos , Suplementos Dietéticos , Hipercolesterolemia/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Hipolipemiantes/administración & dosificación , Mediadores de Inflamación/sangre , Lípidos/sangre , Antiinflamatorios/efectos adversos , Biomarcadores/sangre , Glucemia/metabolismo , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/prevención & control , Estudios Cruzados , Suplementos Dietéticos/efectos adversos , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/complicaciones , Hipercolesterolemia/diagnóstico , Hipoglucemiantes/efectos adversos , Hipolipemiantes/efectos adversos , Italia , Masculino , Persona de Mediana Edad , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
8.
Biol Trace Elem Res ; 177(2): 331-344, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27854046

RESUMEN

Fluoride toxicity is known to pose infertility in fluoride-intoxicated animals as well as in people residing in fluoride endemic zones. The present study addresses the degree of impairments caused due to co-exposure of high fluoride toxicity in diabetic mice. Swiss mice, Mus musculus, were subjected to fluoride toxicity by providing fluoride-supplemented drinking water (600 ppm NaF) for a period of 30 days after the confirmation of streptozotocin-induced diabetes(STZ, 50 mg/kgbw). Consequently, aggravated hyperglycemia and tissue fluoride accumulation were witnessed in fluoride-intoxicated diabetic mice; later, these toxicated mice were treated with ginseng extract (GE) and banaba leaf extract, (BLE) at dose of 150 mg/kgbw/day alone and in combination for 15 and 30-day duration to check the efficacy of phytoextracts in reversing the toxicity. The spermatological indices studied, such as sperm density, motility, viability and morphology as well as the testicular biochemical parameters showed enhanced impairment in reproductive status of fluoride-intoxicated diabetic mice. Further, 15-days administration of GE and BLE in combination at a dose of 150 mg/kgbw/day was found to be beneficial in normalizing the alterations observed upon fluoride intoxication to diabetic mice. However, the correlates showed moderate association between blood glucose levels and the spermatological as well as biochemical indices wherein the tissue fluoride levels correlate least.


Asunto(s)
Diabetes Mellitus Experimental/prevención & control , Fluoruros/toxicidad , Lagerstroemia/química , Panax/química , Extractos Vegetales/farmacología , Espermatozoides/efectos de los fármacos , Testículo/efectos de los fármacos , Administración Oral , Animales , Diabetes Mellitus Experimental/inducido químicamente , Fluoruros/administración & dosificación , Fluoruros/análisis , Masculino , Ratones , Extractos Vegetales/administración & dosificación , Hojas de la Planta/química , Estreptozocina
9.
Phytother Res ; 30(4): 681-8, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26871553

RESUMEN

This 60-day, 30-subject pilot study examined a novel combination of ingredients in a unique sustained release (Carbopol matrix) tablet consumed twice daily. The product was composed of extracts of banaba leaf, green coffee bean, and Moringa oleifera leaf and vitamin D3. Safety was assessed using a 45-measurement blood chemistry panel, an 86-item self-reported Quality of Life Inventory, bone mineral density, and cardiovascular changes. Efficacy was assessed by calculating a body composition improvement index (BCI) based on changes in dual energy X-ray absorptiometry measured fat mass (FM) and fat-free mass (FFM) as well as between the study group (SG) and a historical placebo group. No changes occurred in any blood chemistry measurements. Positive changes were found in the Quality of Life (QOL) inventory composite scores. No adverse effects were observed. Decreases occurred in FM (p = 0.004) and increases in FFM (p = 0.009). Relative to the historical placebo group, the SG lost more FM (p < 0.0001), gained more FFM (p = <0.0001), and had a negative BCI of -2.7 lb. compared with a positive BCI in the SG of 3.4 lb., a 6.1 discordance (p = 0.0009). The data support the safety and efficacy of this unique product and demonstrate importance of using changes in body composition versus scale weight and BMI.


Asunto(s)
Composición Corporal , Mantenimiento del Peso Corporal/efectos de los fármacos , Café/química , Suplementos Dietéticos , Moringa oleifera/química , Extractos Vegetales/farmacología , Presión Sanguínea , Densidad Ósea/efectos de los fármacos , Colecalciferol/química , Preparaciones de Acción Retardada/química , Humanos , Proyectos Piloto , Hojas de la Planta/química , Calidad de Vida , Comprimidos
10.
Artículo en Inglés | WPRIM | ID: wpr-963380

RESUMEN

1. Oral administration of the decoction of banaba with doses equivalent to 1.0 or 2 gm. of dried leaves per kg. body weight reduces blood sugar from 16 to 49 mg. of glucose per 100 cc. of blood in normal rabbits. The maximum reduction occured two hours after administration of the decoction and the blood sugar returned to normal within four to six hours. Repetition of the dose after two to two and a half hours caused the blood sugar level to remain low or to become even lower than the previous effect for four to five hours or more2. Large doses, as 10 to 20 gm. per kg. body weight, produced greater reduction, ranging from 40 to 58 mg. per 100 cc. of blood, but in all these experiments the blood sugar lowering has never reached the convulsive level, and the lowest blood sugar level recorded was 57 mg. per 100 cc. of blood. The maximum reduction after large doses occured from two to four hours after administration of the decoction and the blood sugar returned to normal, judging from the indications in the graph, in six to ten hours3. The blood sugar reduction caused by the decoction of banaba was relatively greater when the initial blood sugar was high than when the initial amount was low4. When the effects on different animals are compared with each other, it may be seen that a small dose in one animal may produce a greater reduction of blood sugar than is produced by a large dose in another animal. When, however, the effects of different doses on the same animal are compared with each other, the true biological reaction produced by increasing dosage of a drug is observed, that is, greater effect for greater dosage5. The absence of important plant constituents suggests that the hypoglycemic principle is probably a hormone occuring in plants similar to insulin occuring in animals. This hypoglycemic principle, however, is not glucokinin, for the plant extracts prepared by Collip, which he considered to contain glucokinin, produced a delayed hypoglycemic effect, twenty-one hours or more after administration of the extract. In case of the decoction of banaba, the hypoglycemic effect was immediate, similar to that produced by subcutaneous injection of insulin6. The following differences of the decocoction of banaba from insulin may be mentioned: a. Insulin is thermolabile whereas the hypoglcemic principle in banaba leaves is thermostable.-b. Oral administration of the decoction of banaba produces hypoglycemic effect whereas oral administration of insulin does notc. Oral administration of large doses of the decoction of banaba have never been observed to produce convulsions or any toxic effect, whereas insulin parenterally injected in large doses is known to produce convulsions or death.(Summary and Conclusions)

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA